Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone M Goldinger

Showing results (21-30 of 69) with videos related to

Pageof 7
Sort By:
Current Oncology Reports|September 26, 2018
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the GlobeFlorentia Dimitriou, Regina Krattinger, Egle Ramelyte, et al.
Dermatology (Basel, Switzerland)|December 1, 2015
Noncutaneous Melanomas: A Single-Center AnalysisValerio Del Prete, Karla Chaloupka, David Holzmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 TherapySimone M Goldinger, Pascale Stieger, Barbara Meier, et al.
Melanoma Research|November 6, 2010
The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label studyLaurence Imhof, Simone M Goldinger, Katrin Baumann, et al.
The Journal of Dermatology|June 6, 2015
Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanomaShigeto Matsushita, Lukas Krähenbühl, Atsushi Otsuka, et al.
Immunotherapy|February 19, 2013
Melanoma immunotherapy: historical precedents, recent successes and future prospectsMarieke I G Raaijmakers, Sima Rozati, Simone M Goldinger, et al.
JAMA Dermatology|March 24, 2016
Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical TrialSimone M Goldinger, Sharon Gobbi Bischof, Regina Fink-Puches, et al.
Plos One|March 22, 2013
RASopathic skin eruptions during vemurafenib therapyJeannine D Rinderknecht, Simone M Goldinger, Sima Rozati, et al.
European Journal of Cancer (Oxford, England : 1990)|November 24, 2024
An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanomaJames P Pham, Ramon Staeger, Anthony M Joshua, et al.
The Australasian Journal of Dermatology|December 7, 2021
Merkel cell carcinoma in situ: A systematic review of prognosis and managementKelvin Truong, Simone M Goldinger, Shaun Chou, et al.
Pageof 7

Showing results (21-30 of 69) with videos related to

Sort By:
Pageof 7
Current Oncology Reports|September 26, 2018
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the GlobeFlorentia Dimitriou, Regina Krattinger, Egle Ramelyte, et al.
Dermatology (Basel, Switzerland)|December 1, 2015
Noncutaneous Melanomas: A Single-Center AnalysisValerio Del Prete, Karla Chaloupka, David Holzmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 TherapySimone M Goldinger, Pascale Stieger, Barbara Meier, et al.
Melanoma Research|November 6, 2010
The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label studyLaurence Imhof, Simone M Goldinger, Katrin Baumann, et al.
The Journal of Dermatology|June 6, 2015
Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanomaShigeto Matsushita, Lukas Krähenbühl, Atsushi Otsuka, et al.
Immunotherapy|February 19, 2013
Melanoma immunotherapy: historical precedents, recent successes and future prospectsMarieke I G Raaijmakers, Sima Rozati, Simone M Goldinger, et al.
JAMA Dermatology|March 24, 2016
Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical TrialSimone M Goldinger, Sharon Gobbi Bischof, Regina Fink-Puches, et al.
Plos One|March 22, 2013
RASopathic skin eruptions during vemurafenib therapyJeannine D Rinderknecht, Simone M Goldinger, Sima Rozati, et al.
European Journal of Cancer (Oxford, England : 1990)|November 24, 2024
An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanomaJames P Pham, Ramon Staeger, Anthony M Joshua, et al.
The Australasian Journal of Dermatology|December 7, 2021
Merkel cell carcinoma in situ: A systematic review of prognosis and managementKelvin Truong, Simone M Goldinger, Shaun Chou, et al.
Pageof 7